Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Esanex

Status and phase: Completed; Phase 1

Conditions: Solid Tumor Malignancy; Lymphoid Malignancy (Lymphoma and CLL); Lymphoma; Leukemia

Treatments: Drug: SNX-5422 Mesylate Hsp90 inhibitor

Study type: Interventional

Funder types: Industry; NIH

Identifiers

NCT00647764

B1311003

PO7318

Details and patient eligibility

About

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Enrollment: 32 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Solid tumors or lymphoid malignancies refractory to standard therapy
• measurable disease
• recovery to Grade < 1 toxicity due to prior adverse event or chemotherapy
• no chemotherapy within 4 weeks of entering study
• Age > 18 years
• Karnofsy >= 60%
• Life expectancy > 3 months
• normal or adequate organ and marrow function

Exclusion criteria

• receiving other investigational agents
• brain metastases
• uncontrolled medical illness
• HIV+ receiving combination antiretroviral therapy
• significant GI disease

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

32 participants in 1 patient group

Single Arm

Experimental group

Treatment:

Drug: SNX-5422 Mesylate Hsp90 inhibitor